Author pages are created from data sourced from our academic publisher partnerships and public sources.
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.
The majority of neuroendocrine tumors originate in the digestive system and incidence is increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis and clinical… Expand
Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor…
Objectives: There is no consensus regarding optimal follow-up in resected gastroenteropancreatic neuroendocrine tumours (NETs). We aimed to perform a practice survey to ascertain follow-up patterns… Expand
Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors
Objectives Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available.… Expand
Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
Background/Objectives In the era of somatostatin analogues and targeted therapies, the role of chemotherapy in NET remains largely undefined. This systematic review aimed to assess the effect of… Expand
Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors
compared with drug-ADR pairs with no known associations to calibrate the threshold at which the PRR represents true ADR signal.3 To establish time-to-detection comparisons against… Expand
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors
There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in… Expand
Everolimus in the management of metastatic neuroendocrine tumours
Neuroendocrine tumours are increasing in incidence and cause a variety of symptoms. The mammalian target of rapamycin (mTOR) pathway plays a key role in neuroendocrine tumour (NET) pathogenesis,… Expand
Principles of diagnosis and management of neuroendocrine tumours
Neuroendocrine tumours (NETs) are a unique group of malignant growths, best known for their ability to secrete bioactive peptides, which may cause symptoms such as flushing and diarrhea. Although… Expand
New drug developments in metastatic gastric cancer
- A. C. Tan, D. Chan, W. Faisal, N. Pavlakis
- Therapeutic advances in gastroenterology
- 14 November 2018
Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of… Expand
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
OBJECTIVES The role of anti-angiogenic tyrosine kinase inhibitors (AATKI) for patients with non-small-cell lung cancers (NSCLC) is uncertain. We conducted a comprehensive meta-analysis to assess the… Expand